Searle v. Biocraft
Executive Summary
Searle announced that it has been granted a hearing in the New Jersey Federal Court on its claim that Biocraft infringed its Norpace (disopyramidel patent. FDA approved Biocraft's generic version of the antihypertensive in February ("The Pink Sheet" Feb. 25, p. 8).